Background and clinical findings in the patients with Parkinson’s disease
| No | Age (years) | Sex | Duration (years) | Yahr’s scale | Autonomic symptoms | Anti-parkinsonian drugs | Body mass index (kg/m2) |
|---|---|---|---|---|---|---|---|
| C, constipation; F, female; H, hyperhidrosis; L+C, levodopa+carbidopa; M, male; OD, orthostatic dizziness; OH, orthostatic hypotension; UF, urinary frequency. | |||||||
| 1 | 53 | M | 4 | 2.5 | C, UF | L+C 300 mg, pergolide 150 μg | 23.1 |
| 2 | 56 | M | 5 | 3.0 | C, UF | L+C 300 mg, pergolide 500 μg, trihexyphenidyl 4 mg | 22.2 |
| 3 | 57 | F | 5 | 3.0 | C, H | L+C 300 mg, amantadine 150 mg | 24.7 |
| 4 | 58 | F | 6 | 3.0 | C, UF | L+C 500 mg, pergolide 150 μg | 22.2 |
| 5 | 58 | F | 5 | 3.0 | H | L+C 400 mg, pergolide 750 μg | 24.6 |
| 6 | 62 | F | 7 | 3.0 | C | L+C 400 mg, pergolide 500 μg | 21.6 |
| 7 | 63 | F | 8 | 4.0 | H | L+C 300 mg, amantadine 100 mg | 20.2 |
| 8 | 66 | F | 6 | 3.0 | C, UF | L+C 500 mg, pergolide 150 μg, trihexyphenidyl 6 mg | 20.8 |
| 9 | 69 | F | 4 | 2.5 | C, UF | L+C 200 mg, trihexyphenidyl 6 mg | 20.5 |
| 10 | 72 | F | 5 | 3.0 | C | L+C 300 mg, amantadine 100 mg | 24.5 |
| 11 | 72 | M | 8 | 4.0 | C, UF | L+C 400 mg, amantadine 150 mg | 23.0 |
| 12 | 75 | M | 9 | 3.0 | (-) | L+C 300 mg, pergolide 150 μg | 22.3 |
| 13 | 78 | F | 4 | 4.0 | C, UF, H | L+C 200 mg,, amantadine 150 mg | 20.4 |
| 14 | 79 | F | 10 | 4.0 | C, UF, OD | L+C 400 mg, pergolide 150 μg, trihexyphenidyl 2 mg | 19.2 |
| 15 | 86 | F | 12 | 4.0 | C, OD | L+C 500 mg, pergolide 150 μg, trihexyphenidyl 4 mg | 20.0 |
| 16 | 69 | M | 7 | 3.0 | C, OH | L+C 500 mg, pergolide 300 μ | 24.0 |
| 17 | 73 | M | 8 | 4.0 | C, UF, OH | L+C 450 mg, trihexyphenidyl 6 mg | 18.4 |
| 18 | 76 | F | 12 | 4.0 | C, UF, OH | L+C 300 mg, pergolide 150 μg | 21.1 |